A special section titled “Cannabinoid Signaling in Human Health and Disease” is being planned for publication in the November 2024 issue of The Journal of Pharmacology and Experimental Therapeutics.

This special issue will serve as a dedicated forum for original research on various aspects of cannabinoid signaling in disease states, including but not limited to chronic pain, neuropsychiatric disease, addiction and cardiovascular health. Research on cannabinoid signaling has undergone tremendous growth since the discovery of endogenous receptors and their endocannabinoid ligands. This research has demonstrated important roles for cannabinoid signaling in many physiological processes, including feeding and metabolism, reward signaling and addiction, cardiovascular function, pain response, affective and emotional regulation and many others.

The recent widespread legalization of cannabis and cannabinoids for medical and recreational use makes it imperative to make further advances regarding our understanding of the role of cannabinoids in human health. The scope of the original research in this special issue can include work done in preclinical animal models as well as clinical studies in human populations.

Original articles addressing any aspects of the topics or the role of cannabinoids in additional facets of human health will be considered. Although not required for publication, authors can send a pre-submission inquiry including the title, abstract, significance statement, and full author information, to The Journal of Pharmacology and Experimental Therapeutics in advance of full submission. The guest editors, Drs. Daniel Morgan and Josée Guindon will review these inquiries and respond to the authors with comments and suggestions for a full submission.

The submission deadline is February 2024. All submissions must refer to the journal’s Instructions to Authors for specific guidelines on research articles.